Literature DB >> 3542205

Domperidone and Parkinson's disease.

J D Parkes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3542205     DOI： 10.1097/00002826-198612000-00003

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  12 in total

Review 1.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

Review 2.  [Nonmotor symptoms in Parkinson's disease].

Authors:  W H Jost
Journal:  Nervenarzt       Date:  2017-08       Impact factor: 1.214

Review 3.  Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management.

Authors:  W H Jost
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 4.  Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease.

Authors:  Lindy D Wood
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

5.  Dopamine, urges to smoke, and the relative salience of drug versus non-drug reward.

Authors:  Tom P Freeman; Ravi K Das; Sunjeev K Kamboj; H Valerie Curran
Journal:  Soc Cogn Affect Neurosci       Date:  2014-02-12       Impact factor: 3.436

Review 6.  [Gastrointestinal dysfunction in idiopathic Parkinson's disease].

Authors:  K Del Tredici; W H Jost
Journal:  Nervenarzt       Date:  2012-10       Impact factor: 1.214

7.  Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine.

Authors:  Marina Braun; Willi Cawello; Hilmar Boekens; Rolf Horstmann
Journal:  Br J Clin Pharmacol       Date:  2008-12-16       Impact factor: 4.335

8.  Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects.

Authors:  Joëlle Micallef; Marc Rey; Alexandre Eusebio; Christine Audebert; Frank Rouby; Elisabeth Jouve; Sophie Tardieu; Oliver Blin
Journal:  Br J Clin Pharmacol       Date:  2008-09-19       Impact factor: 4.335

9.  Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.

Authors:  M M Mouradian; I J Heuser; F Baronti; M Giuffra; K Conant; T L Davis; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

Review 10.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.